drugset / Trial / NCT00831077

Early Phase I Microdosing Study of ORM-14540 and ORM-12741

NCT00831077 ↗

Phase 0 Completed 6 enrolled Orion Corporation, Orion Pharma
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine pharmacokinetic parameters of ORM-12741 and ORM-14540 in healthy volunteers.

Timeline

Start
2009-01
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator ORM-12741 Small molecule — Intravenous
Comparator ORM-14540 Unknown — Intravenous

Indications

No indication recorded.